Considerations for a business model for the effective integration of novel biomarkers into drug development

ISSN： 1741-0541

Source： Personalized Medicine, Vol.5, Iss.6, 2008-11, pp. : 641-649

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Biomarkers of Drug‐Induced Kidney Injury

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 3, 2018-03 ,pp. : 396-398

John Wiley & Sons Inc

Access to resources Recommend Favorite

Considerations on clinical trials of leprosy treatment: need of novel drug combinations

By Illarramendi Ximena de Oliveira Maria Leide Wand del Rey Sales Anna Maria da Costa Nery José Augusto Sarno Euzenir Nunes

Clinical Investigation, Vol. 3, Iss. 7, 2013-07 ,pp. : 617-635

Future Science

Access to resources Recommend Favorite

Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 147-149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effective Biomarkers for Proof-of-Concept

Current Medical Imaging Reviews, Vol. 4, Iss. 1, 2008-02 ,pp. : 25-27

Bentham Science Publishers

Access to resources Recommend Favorite

Novel approaches to address challenges in global drug development

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 3, 2015-03 ,pp. : 196-199

John Wiley & Sons Inc

Access to resources Recommend Favorite